Evaluation of non-measurable/non-target lesions. Complete response (CR): disappearance of all non-target lesions • Incomplete response/stable disease (SD): persistence of one or more non-target lesion(s) • Progressive disease (PD): appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions
Appears in 2 contracts
Sources: Clinical Trial Collaboration and Supply Agreement (Nugenerex Immuno-Oncology, Inc.), Clinical Trial Collaboration and Supply Agreement (Generex Biotechnology Corp)